Company unveils mega launch plan

Posted 17 April 2024 PM

Boehringer Ingelheim has unveiled an ambitious plan for 25 new product launches by 2030 as its bumper late-stage pipeline bears fruit, with 10 new Phase 2 and 3 trials scheduled to kick off in the next 12 to 18 months.

The company reported strong growth in 2023 with pharma sales up 10.3 per cent driven by Jardiance for type 2 diabetes and heart failure, which recorded an impressive boost in sales of 31 per cent to bring in 7.4 billion euros (AU$12.2 billion). Ofev, for idiopathic pulmonary fibrosis and certain fibrosing interstitial lung disease, was another big earner with a 12.8 per cent increase in sales, bringing in revenues of 3.5 billion euros (AU$5.8 billion).

To see the whole article, please login